TNFRSF17 and plasma cell myeloma: BCMA is only expressed on late B cells, normal plasma cells, and multiple myeloma cells, and not on hematopoietic stem cells, which makes it an ideal cancer associated antigen to target by immunotherapy (14, 16–18).